Core Viewpoint - Dongyangguang Pharmaceutical has made significant strides in the field of innovative drug development, particularly with its core drug HECN30227, which offers hope for clinical cure for hepatitis B patients in China [2][3]. Company Development - Established in 2003, Dongyangguang Pharmaceutical has transformed from a generic drug brand to a comprehensive pharmaceutical company focused on innovative drugs, targeting areas such as infections, chronic diseases, and tumors [2][3]. - The company has developed three self-researched new drugs and has nearly 50 new drugs in the pipeline, actively seeking international expansion for growth [3][4]. Financial Performance - From 2022 to 2024, the total revenue is projected to reach 14.2 billion yuan, with research and development investment amounting to 2.5 billion yuan over the past three years, and profits exceeding 2.1 billion yuan in the last two years [4][5]. Innovation and R&D - The company emphasizes the long-term commitment required for innovative drug development, with the first new drug, phosphoric acid emetine, taking ten years from project initiation to market launch [5]. - Dongyangguang Pharmaceutical has a robust R&D system, including a modern factory with an annual production capacity of 1.8 billion tablets and a national key laboratory for new anti-infection drug research [6]. AI and Digitalization - The company is actively integrating AI into its drug discovery process, having established a partnership with Huawei Cloud and DeepMind Technology to create an "AI + biomedicine" ecosystem [7]. International Expansion - Dongyangguang Pharmaceutical aims to expand internationally, with a sales network covering eight countries, including the US, Germany, and the UK [9][10]. - The company has three clear pathways for international growth: internationalization of mature products, authorized cooperation for innovative drugs, and overseas market entry for self-developed products [10]. Commitment to Quality - Dongyangguang Pharmaceutical is committed to providing high-quality, affordable insulin products for the global diabetes population, aiming to be the first domestic company to obtain approval for its insulin products in the US [10][11].